MCID: ANG015
MIFTS: 58

Angioedema

Categories: Bone diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Oral diseases, Rare diseases, Skin diseases

Aliases & Classifications for Angioedema

MalaCards integrated aliases for Angioedema:

Name: Angioedema 12 77 56 6 45 15 17 74
Quincke's Edema 12 77
Angioneurotic Oedema 12
Angioneurotic Edema 12
Giant Urticaria 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1558
MeSH 45 D000799
NCIt 51 C112175
SNOMED-CT 69 41291007 82966003
ICD10 34 T78.3
UMLS 74 C0002994

Summaries for Angioedema

Disease Ontology : 12 A skin disease characterized by the rapid swelling of the dermis, subcutaneous tissue, mucosa and submucosal tissues.

MalaCards based summary : Angioedema, also known as quincke's edema, is related to acquired angioedema and angioedema, hereditary, type i, and has symptoms including edema and peau d'orange. An important gene associated with Angioedema is F12 (Coagulation Factor XII), and among its related pathways/superpathways are Collagen chain trimerization and Peptide hormone metabolism. The drugs Omalizumab and Icatibant have been mentioned in the context of this disorder. Affiliated tissues include skin, tongue and testes.

Wikipedia : 77 Angioedema is an area of swelling of the lower layer of skin and tissue just under the skin or mucous... more...

Related Diseases for Angioedema

Diseases in the Angioedema family:

Angioedema, Hereditary, Type I Angioedema, Hereditary, Type Iii
Hereditary Angioedema Acquired Angioedema
Acquired Angioedema Type 1 Acquired Angioedema Type 2

Diseases related to Angioedema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 263)
# Related Disease Score Top Affiliating Genes
1 acquired angioedema 34.2 C1S SERPING1
2 angioedema, hereditary, type i 34.2 F12 SERPING1
3 hereditary angioedema 33.1 ACE BDKRB2 C1S F12 KLKB1 KNG1
4 c1 inhibitor deficiency 32.7 BDKRB2 C1S KLKB1 KNG1 SERPING1
5 allergic urticaria 30.2 KNG1 SERPING1
6 urticaria 29.6 C1S CPN1 F12 HNMT LTC4S PTGS1
7 sinusitis 29.4 IL5 LTC4S
8 eosinophilia-myalgia syndrome 29.3 HNMT IL5
9 myocardial infarction 28.8 ACE KNG1 MME PTGS1 PTGS2
10 angioedema, hereditary, type iii 12.6
11 angioedema induced by ace inhibitors 12.6
12 episodic angioedema with eosinophilia 12.4
13 hereditary angioedema with normal c1inh 12.2
14 hereditary angioedema with c1inh deficiency 12.1
15 acquired angioedema type 2 12.1
16 vibratory urticaria 12.1
17 acquired angioedema with c1inh deficiency 12.0
18 acquired angioedema type 1 12.0
19 complement component 4, partial deficiency of 11.5
20 carboxypeptidase n deficiency 11.0
21 netherton syndrome 11.0
22 loiasis 11.0
23 lupus erythematosus 10.4
24 hypereosinophilic syndrome 10.3
25 systemic lupus erythematosus 10.3
26 lymphoma 10.3
27 vasculitis 10.2
28 peroneal neuropathy 10.2 CPN1 MME
29 asthma 10.1
30 hepatitis 10.1
31 pancreatitis 10.1
32 oxirane allergy 10.1
33 granulocytopenia 10.1
34 drug-induced lupus erythematosus 10.1 F12 KLKB1
35 arthritis 10.1
36 dermatitis 10.1
37 malignant essential hypertension 10.1 ACE KLKB1 KNG1
38 renal hypertension 10.1 ACE KLKB1 KNG1
39 crohn's disease 10.1
40 contact dermatitis 10.1
41 chronic tic disorder 10.1 F12 IL5
42 acute pancreatitis 10.0
43 allergic contact dermatitis 10.0
44 ischemia 10.0
45 childhood type dermatomyositis 10.0
46 dermatomyositis 10.0
47 hypothyroidism 10.0
48 fibrillary glomerulonephritis 10.0
49 congestive heart failure 10.0 ACE KNG1 MME
50 intussusception 10.0

Graphical network of the top 20 diseases related to Angioedema:



Diseases related to Angioedema

Symptoms & Phenotypes for Angioedema

UMLS symptoms related to Angioedema:


edema, peau d'orange

Drugs & Therapeutics for Angioedema

Drugs for Angioedema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 308)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 242138-07-4
2
Icatibant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 130308-48-4, 138614-30-9 71364
3
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
4
Histamine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 51-45-6 774
5
Loratadine Approved, Investigational Phase 4,Phase 2 79794-75-5 3957
6
Enalaprilat Approved Phase 4,Not Applicable 76420-72-9 6917719
7
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
8
Angiotensin II Approved, Investigational Phase 4,Phase 2,Phase 3 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
9
Enalapril Approved, Vet_approved Phase 4,Not Applicable 75847-73-3 5362032 40466924
10
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
11
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 1 22916-47-8 4189
12
Sirolimus Approved, Investigational Phase 4 53123-88-9 46835353 6436030 5284616
13
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
14
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
15
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
16
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
17
Zinc Approved, Investigational Phase 4,Phase 3 7440-66-6 32051
18
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
19
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
20
Pantoprazole Approved Phase 4 102625-70-7 4679
21
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
22
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
23
Tranexamic Acid Approved Phase 4,Phase 3 1197-18-8 5526
24
Levocetirizine Approved Phase 4,Phase 3 130018-77-8 1549000
25
Cetirizine Approved Phase 4,Phase 3 83881-51-0 2678
26
Histidine Approved, Nutraceutical Phase 4 71-00-1 6274
27
Bradykinin Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-82-2 439201
28
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
29
Lactitol Investigational Phase 4,Phase 2 585-86-4, 585-88-6 493591
30 Vaccines Phase 4,Phase 2
31 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1
32 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Kininogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
43 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
47 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
48 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
49 Respiratory System Agents Phase 4,Phase 3,Phase 2,Not Applicable
50 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 197)
# Name Status NCT ID Phase Drugs
1 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
2 A Call Center During HAE Attacks (SOS HAE) Completed NCT01679912 Phase 4
3 A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE Completed NCT00914966 Phase 4
4 Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE Completed NCT01457430 Phase 4 Icatibant
5 Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert Completed NCT01467947 Phase 4
6 Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria Completed NCT01444196 Phase 4 Desloratadine
7 Comparison of Saocubitril/valsartaN Versus Enalapril on Effect on ntpRo-bnp in Patients Stabilized From an Acute Heart Failure Episode. Completed NCT02554890 Phase 4 sacubitril/valsartan (LCZ696);Enalapril;sacubitril/valsartan (LCZ696) matching placebo;enalapril matching placebo
8 Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine Completed NCT01567865 Phase 4
9 Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus Completed NCT00502242 Phase 4 ramipril;ramipril
10 Steroids in Fulminant Hepatitis A in the Pediatric Age Group Completed NCT02375867 Phase 4 prednisolone;methylprednisolone
11 Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment Completed NCT02550106 Phase 4 OMALIZUMAB
12 Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety Completed NCT00359801 Phase 4 Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care;Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care
13 Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy Completed NCT01917149 Phase 4 Benazepril;Valsartan;Metoprolol
14 Stress Ulcer Prophylaxis in the Intensive Care Unit Completed NCT02467621 Phase 4 Pantoprazole
15 Use of an Antiemetic to Shorten the Length of Labor in Nulliparous Women Completed NCT01937234 Phase 4 Metoclopramide;Placebo
16 Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy Recruiting NCT02966314 Phase 4 Omalizumab;Placebos
17 A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions Recruiting NCT03576469 Phase 4
18 Tranexamic Acid and Spontaneous Chronic Urticaria Not yet recruiting NCT03789422 Phase 4 association of levocetirizine and tranexamic acid;Levocetirizine only
19 Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema Terminated NCT01574248 Phase 4 icatibant
20 C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation Withdrawn NCT01151735 Phase 4 C-1-esterase;C-1-esterase;placebo
21 Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE Completed NCT02586805 Phase 3 DX-2930 - 300mg/2wk;DX-2930 - 300mg/4wk;DX-2930 - 150mg/4wk;Placebo
22 A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema Completed NCT01912456 Phase 3
23 Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema Completed NCT02052141 Phase 3
24 Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema Completed NCT01919801 Phase 3 Icatibant;Placebo
25 Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy Completed NCT01723072 Phase 3 Placebo
26 Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema Completed NCT02584959 Phase 3 C1 esterase inhibitor [human] liquid;Placebo
27 C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema Completed NCT00125151 Phase 3 C1 inhibitor concentrate (C1-esteraseremmer-N)
28 C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema Completed NCT00125541 Phase 2, Phase 3 C1 inhibitor concentrate (C1-esteraseremmer-N)
29 A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants Completed NCT03888755 Phase 3 Icatibant
30 A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema Completed NCT01386658 Phase 3 icatibant
31 Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks Completed NCT00438815 Phase 3
32 Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks Completed NCT00462709 Phase 3
33 Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema Completed NCT00097695 Phase 3 Icatibant;Placebo
34 A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3) Completed NCT00912093 Phase 3 Icatibant;Placebo
35 Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE) Completed NCT02865720 Phase 3 CINRYZE 500 U;CINRYZE 1000 U
36 A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema Completed NCT02316353 Phase 3
37 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks Completed NCT02303626 Phase 2, Phase 3 BCX4161;Placebo
38 Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE) Completed NCT00456508 Phase 3 ecallantide
39 Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE) Completed NCT00457015 Phase 3 ecallantide;Phosphate Buffer Saline (PBS), pH 7.0
40 Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00225147 Phase 2, Phase 3 Recombinant Human C1 Inhibitor;placebo
41 C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks Completed NCT01005888 Phase 3 Placebo (saline)
42 Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE) Completed NCT00500656 Phase 3 Icatibant;Tranexamic Acid;Oral Placebo;S.C. Placebo
43 Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00262301 Phase 3 recombinant human C1 inhibitor;Placebo
44 C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study) Completed NCT00292981 Phase 3 C1 Esterase Inhibitor
45 Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00262288 Phase 2, Phase 3 i.v. recombinant human C1 inhibitor
46 Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks Completed NCT01188564 Phase 3 rhC1INH;Placebo (Saline)
47 EASSI - Evaluation of the Safety of Self-Administration With Icatibant Completed NCT00997204 Phase 3 Icatibant
48 Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE) Completed NCT00262080 Phase 3 ecallantide;Phosphate Buffer Saline (PBS),
49 Berinert P Study of Subcutaneous Versus Intravenous Administration Completed NCT00748202 Phase 3 C1-Esterase Inhibitor
50 Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks Completed NCT00168103 Phase 2, Phase 3

Search NIH Clinical Center for Angioedema

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: angioedema

Genetic Tests for Angioedema

Anatomical Context for Angioedema

MalaCards organs/tissues related to Angioedema:

42
Skin, Tongue, Testes, Liver, Heart, Brain, Kidney

Publications for Angioedema

Articles related to Angioedema:

(show top 50) (show all 2840)
# Title Authors Year
1
Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate. ( 30866985 )
2019
2
Hereditary angioedema in Austria: prevalence and regional peculiarities. ( 30883006 )
2019
3
Anesthetic Management of a Patient With Hereditary Angioedema for Oral Surgery. ( 30883234 )
2019
4
Serum fetuin-A, tumor necrosis factor alpha and C-reactive protein concentrations in patients with hereditary angioedema with C1-inhibitor deficiency. ( 30885236 )
2019
5
Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks. ( 30899278 )
2019
6
Reporting through smartphone application results in detailed data on acquired and hereditary angioedema attacks. ( 30908664 )
2019
7
Current and emerging biologics for the treatment of hereditary angioedema. ( 30912460 )
2019
8
Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey. ( 30176179 )
2019
9
Angioedema and emergency medicine: From pathophysiology to diagnosis and treatment. ( 30220453 )
2019
10
Bradykinin mechanism is the main responsible for death by isolated asphyxiating angioedema in France. ( 30326160 )
2019
11
Training patients for self-administration of a new subcutaneous C1-inhibitor concentrate for hereditary angioedema. ( 30534402 )
2019
12
Pharmacogenetics of angiotensin-converting enzyme inhibitor-induced angioedema. ( 30537422 )
2019
13
Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies. ( 30539362 )
2019
14
Angioedema of the small bowel caused by lisinopril. ( 30567854 )
2019
15
New and evolving therapies for hereditary angioedema. ( 30582490 )
2019
16
Hereditary angioedema: Linking complement regulation to the coagulation system. ( 30656274 )
2019
17
Treatment Effect of Switching from Intravenous to Subcutaneous C1-inhibitor for Prevention of Hereditary Angioedema Attacks: COMPACT Subgroup Findings. ( 30660873 )
2019
18
Isolated angioedema: An overview of clinical features and etiology. ( 30679975 )
2019
19
Angiopoietin-1 haploinsufficiency affects the endothelial barrier and causes hereditary angioedema. ( 30689269 )
2019
20
Delayed Diagnosis of Hereditary Angioedema with C1-inhibitor Deficiency in Iranian Children and Adolescents. ( 30690789 )
2019
21
Oxidative stress markers in patients with hereditary angioedema. ( 30697258 )
2019
22
Angioedema after thrombolysis with tissue plasminogen activator: an airway emergency. ( 30697429 )
2019
23
The Effectiveness and Value of Lanadelumab and C1 Esterase Inhibitors for Prophylaxis of Hereditary Angioedema Attacks. ( 30698087 )
2019
24
Cost-Effectiveness of Prophylactic Medications for the Treatment of Hereditary Angioedema Due to C1 Inhibitor Deficiency: A Real-World U.S. Perspective. ( 30698094 )
2019
25
Is hereditary angioedema related to an increased risk of atherosclerosis? ( 30711037 )
2019
26
C1-INH concentrate for prophylaxis during pregnancy in hereditary angioedema with normal C1-INH. ( 30717879 )
2019
27
A Forgotten Cause of Allergy at ER That Is Still Difficult to Diagnose and Treat at Poor Resource Setting: Angioedema after Using Angiotensin Converting Enzyme Inhibitors for 4 Years. ( 30723559 )
2019
28
Hereditary angioedema: Repeated attacks in a 10-year-old boy. ( 30734432 )
2019
29
Abnormal T-cell phenotype in episodic angioedema with hypereosinophilia (Gleich's syndrome): frequency, clinical implication and prognosis. ( 30738125 )
2019
30
Idiopathic non-histaminergic angioedema: a single-centre real-life experience from Italy. ( 30740715 )
2019
31
Trends in hospitalizations related to anaphylaxis, angioedema and urticaria in the United States. ( 30769181 )
2019
32
Does angioedema influence the quality of life in chronic spontaneous urticaria patients? ( 30769182 )
2019
33
Laryngeal Edema in a Child with Hereditary Angioedema with Normal C1 Inhibitor. ( 30770337 )
2019
34
Flexible nasotracheal intubation compared to blind nasotracheal intubation in the setting of simulated angioedema. ( 30772130 )
2019
35
Hemilingual Angioedema after Thrombolysis in a Patient on an Angiotensin II Receptor Blocker. ( 30772164 )
2019
36
Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. ( 30772477 )
2019
37
Angioedema following initiation of Glecaprevir/ Pibrentasvir while on Sitagliptin. ( 30779957 )
2019
38
A rare presentation of angioedema with isolated retropharyngeal and supraglottic involvement. ( 30788074 )
2019
39
Identification of the recently described plasminogen gene mutation p.Lys330Glu in a family from Northern Germany with hereditary angioedema. ( 30809376 )
2019
40
Clinical profile and quality of life of Puerto Ricans with hereditary angioedema. ( 30819279 )
2019
41
Hereditary Angioedema may be associated with the development of Fatty liver. ( 30825607 )
2019
42
Hereditary angioedema: a Chinese perspective. ( 30827947 )
2019
43
Chronic spontaneous urticaria and angioedema requiring treatment with omalizumab in a patient with hereditary angioedema. ( 30831259 )
2019
44
Angioedema - Our Experience Focused On Socio-Demographic, Etiological and Clinical Characteristics of the Condition and Its Management. ( 30833998 )
2019
45
Age Characteristics and Concomitant Diseases in Patients with Angioedema. ( 30834003 )
2019
46
Possible Donor-Dependent Differences in Efficacy of Fresh Frozen Plasma for Treatment of ACE Inhibitor-Induced Angioedema. ( 30836229 )
2019
47
Hemifacial angioedema following alteplase for acute stroke. ( 30837301 )
2019
48
Genetic Variation of Kallikrein-Kinin System and Related Genes in Patients With Hereditary Angioedema. ( 30847342 )
2019
49
A case of food-dependent exercise-induced angioedema. ( 29842933 )
2019
50
Desensitization protocol for angioedema induced by encorafenib in a patient with metastatic melanoma. ( 30835914 )
2019

Variations for Angioedema

ClinVar genetic disease variations for Angioedema:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 F12 NM_000505.3(F12): c.983C> G (p.Thr328Arg) single nucleotide variant Pathogenic rs118204456 GRCh37 Chromosome 5, 176831232: 176831232
2 F12 NM_000505.3(F12): c.983C> G (p.Thr328Arg) single nucleotide variant Pathogenic rs118204456 GRCh38 Chromosome 5, 177404231: 177404231
3 SYTL2 NM_032943.4(SYTL2): c.890delG (p.Ser297Thrfs) deletion Pathogenic rs1057519445 GRCh38 Chromosome 11, 85734436: 85734436
4 SYTL2 NM_032943.4(SYTL2): c.890delG (p.Ser297Thrfs) deletion Pathogenic rs1057519445 GRCh37 Chromosome 11, 85445479: 85445479
5 SERPING1 NM_000062.2(SERPING1): c.1475T> C (p.Met492Thr) single nucleotide variant Likely pathogenic rs978962357 GRCh37 Chromosome 11, 57382026: 57382026
6 SERPING1 NM_000062.2(SERPING1): c.1475T> C (p.Met492Thr) single nucleotide variant Likely pathogenic rs978962357 GRCh38 Chromosome 11, 57614553: 57614553

Expression for Angioedema

Search GEO for disease gene expression data for Angioedema.

Pathways for Angioedema

Pathways related to Angioedema according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.46 DPP4 F12 KLKB1 KNG1 MME XPNPEP2
2
Show member pathways
11.97 ACE CPN1 DPP4 MME
3
Show member pathways
11.94 LTC4S PTGS1 PTGS2
4
Show member pathways
11.82 F12 KLKB1 KNG1 SERPING1
5
Show member pathways
11.7 LTC4S PTGS1 PTGS2
6 11.24 BDKRB2 C1S F12 KLKB1 KNG1 SERPING1
7 11.23 F12 KLKB1 SERPING1
8
Show member pathways
11.16 ACE BDKRB2 KNG1 MME
9 11.03 PTGS1 PTGS2
10 10.98 PTGS1 PTGS2
11
Show member pathways
10.96 PTGS1 PTGS2
12 10.87 ACE MME
13 10.86 PTGS1 PTGS2
14 10.76 PTGS1 PTGS2
15 10.71 LTC4S PTGS1 PTGS2
16 10.61 PTGS1 PTGS2

GO Terms for Angioedema

Cellular components related to Angioedema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 ACE C1S CPN1 F12 IL5 KLKB1
2 extracellular region GO:0005576 9.65 ACE C1S CPN1 DPP4 F12 IL5
3 blood microparticle GO:0072562 9.43 C1S KNG1 SERPING1
4 extracellular exosome GO:0070062 9.32 ACE DPP4 F12 HNMT KLKB1 KNG1

Biological processes related to Angioedema according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 regulation of complement activation GO:0030449 9.76 C1S CPN1 SERPING1
2 blood coagulation GO:0007596 9.76 F12 KLKB1 KNG1 SERPING1
3 inflammatory response GO:0006954 9.73 BDKRB2 IL5 KLKB1 KNG1 PTGS1 PTGS2
4 cellular oxidant detoxification GO:0098869 9.67 LTC4S PTGS1 PTGS2
5 regulation of blood pressure GO:0008217 9.65 ACE PTGS1 PTGS2
6 arachidonic acid secretion GO:0050482 9.62 ACE BDKRB2
7 regulation of vasoconstriction GO:0019229 9.61 ACE BDKRB2
8 long-chain fatty acid biosynthetic process GO:0042759 9.61 LTC4S PTGS2
9 prostaglandin metabolic process GO:0006693 9.6 PTGS1 PTGS2
10 vasodilation GO:0042311 9.59 BDKRB2 KNG1
11 prostaglandin biosynthetic process GO:0001516 9.58 PTGS1 PTGS2
12 zymogen activation GO:0031638 9.57 F12 KLKB1
13 peptide metabolic process GO:0006518 9.56 CPN1 MME
14 proteolysis GO:0006508 9.56 ACE C1S CPN1 DPP4 F12 KLKB1
15 amyloid-beta metabolic process GO:0050435 9.55 ACE MME
16 regulation of blood coagulation GO:0030193 9.54 F12 SERPING1
17 angiotensin maturation GO:0002003 9.52 ACE MME
18 cyclooxygenase pathway GO:0019371 9.51 PTGS1 PTGS2
19 fibrinolysis GO:0042730 9.5 F12 KLKB1 SERPING1
20 hemostasis GO:0007599 9.46 F12 KLKB1 KNG1 SERPING1
21 negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress GO:1902219 9.43 BDKRB2 PTGS2
22 positive regulation of fibrinolysis GO:0051919 9.4 F12 KLKB1
23 Factor XII activation GO:0002542 9.37 F12 KLKB1
24 blood coagulation, intrinsic pathway GO:0007597 8.92 F12 KLKB1 KNG1 SERPING1

Molecular functions related to Angioedema according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 hydrolase activity GO:0016787 9.92 ACE C1S CPN1 DPP4 F12 KLKB1
2 serine-type endopeptidase activity GO:0004252 9.71 C1S DPP4 F12 KLKB1
3 heme binding GO:0020037 9.63 KLKB1 PTGS1 PTGS2
4 metallopeptidase activity GO:0008237 9.56 ACE CPN1 MME XPNPEP2
5 peroxidase activity GO:0004601 9.49 PTGS1 PTGS2
6 aminopeptidase activity GO:0004177 9.48 DPP4 XPNPEP2
7 serine-type peptidase activity GO:0008236 9.46 C1S DPP4 F12 KLKB1
8 dipeptidyl-peptidase activity GO:0008239 9.43 ACE DPP4
9 exopeptidase activity GO:0008238 9.37 ACE MME
10 peptidase activity GO:0008233 9.23 ACE C1S CPN1 DPP4 F12 KLKB1
11 prostaglandin-endoperoxide synthase activity GO:0004666 8.96 PTGS1 PTGS2

Sources for Angioedema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....